Phase II study examines the safety and effectiveness of pembrolizumab and olaparib in recurrent cervical cancer, suggesting a need for biomarkers.
Pembrolizumab and Olaparib combination therapy demonstrated an acceptable safety profile. Pembrolizumab plus olaparib showed manageable safety in platinum-experienced recurrent cervical cancer. Adding PARP inhibitor to PD-1 blockade demonstrated limited additional clinical activity in this setting. Appropriate biomarkers may be needed for pembrolizumab plus olaparib.
No takes yet. Share an insight, caveat, or question.
Ogasawara et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: